IP Library Granted Patent US 11,826,521
Granted Patent B2
US 11,826,521 · App. 17/095,108 · Granted Nov 28, 2023

Systems, devices and methods for the creation of a therapeutic restriction in the gastrointestinal tract

Inventors: Harith Rajagopalan (Wellesley Hills, MA); Jay Caplan (Belmont, MA); R. Maxwell Flaherty (Topsfield, MA); J. Christopher Flaherty (Auburndale, FL)
Assignee: Fractyl Health, Inc.
A61M25/0084A61F5/0013A61F5/0076A61K31/728A61K33/42A61K35/33A61K35/35A61K45/06A61L31/043A61L31/048A61L31/06A61L31/145A61L31/16A61M25/00A61M25/0082A61M31/00A61F2005/0016A61M2025/0089A61M2025/0096A61N1/306
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,826,521
App. No.
17/095,108
Granted
Nov 28, 2023
Kind
B2
Abstract

A system for treating a patient comprises a delivery device and injectate. The delivery device comprises an elongate shaft with a distal portion and at least one delivery element positioned on the elongate shaft distal portion. The delivery device is constructed and arranged to deliver the injectate through the at least one delivery element and into tissue to create a therapeutic restriction in the gastrointestinal tract. Methods of creating a therapeutic restriction are also provided.

Claims (18)

1. A system for treating a patient comprising:

a delivery device comprising:

an elongate shaft with a distal portion and at least one delivery element positioned on the elongate shaft distal portion; and

an injectate configured to expand when delivered into tissue;

a sizing device configured to measure a luminal diameter; and

an injectate delivery unit configured to determine an amount of the injectate to be delivered based on the measured luminal diameter in order to narrow a lumen of a segment of an intestine to an inner diameter that is less than or equal to 10 mm;

wherein the delivery device is configured to deliver, based on the determined amount of injectate, the injectate through the at least one delivery element into luminal wall tissue of the intestine to narrow the lumen of the segment of the intestine to the inner diameter that is less than or equal to 10 mm.

2. The system according to claim 1 , wherein the at least one delivery element comprises at least two delivery elements.

3. The system according to claim 2 , wherein the at least two delivery elements comprises at least three delivery elements.

4. The system according to claim 1 , wherein the injectate comprises at least two materials.

5. The system according to claim 1 , wherein the delivery device is configured to deliver the injectate to narrow a lumen of a segment of the intestine to an inner diameter that is less than or equal to 5 mm.

6. The system according to claim 5 , wherein the delivery device is configured to deliver the injectate to narrow a lumen of a segment of the intestine to an inner diameter that is less than or equal to 4 mm.

7. The system according to claim 6 , wherein the delivery device is configured to deliver the injectate to narrow a lumen of a segment of the intestine to an inner diameter that is less than or equal to 3 mm.

8. The system according to claim 1 , wherein the injectate comprises a material selected from the group consisting of: peptide polymer; polylactic acid; polymethylmethacrylate; hydrogel; sclerosant; adhesive; cyanoacrylate; and combinations thereof.

9. The system according to claim 1 , wherein the injectate comprises a material selected from the group consisting of: fat cells; collagen; autologous collagen; bovine collagen; porcine collagen; bioengineered human collagen; dermis; a dermal filler; hyaluronic acid; conjugated hyaluronic acid; calcium hydroxylapatite; fibroblasts; and combinations thereof.

10. The system according to claim 1 , wherein the injectate is further configured to polymerize when delivered into tissue.

11. The system according to claim 1 , wherein the injectate comprises hyaluronic acid.

12. The system according to claim 2 , wherein the luminal wall tissue comprises submucosal tissue.

Assignments (3)
SECURITY INTEREST Recorded Sep 7, 2023
From: FRACTYL HEALTH, INC.
To: SYMBIOTIC CAPITAL AGENCY LLC
Reel/Frame 064840/0561 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2021
From: RAJAGOPALAN, HARITH; CAPLAN, JAY; FLAHERTY, R. MAXWELL; FLAHERTY, J. CHRISTOPHER
To: FRACTYL LABORATORIES, INC.
Reel/Frame 057679/0749 →
CHANGE OF NAME Recorded Oct 2, 2021
From: FRACTYL LABORATORIES, INC.
To: FRACTYL HEALTH, INC.
Reel/Frame 057698/0269 →
Continuity (5)
Continuation 16267771 · Feb 5, 2019
Continuation 15156585 · May 17, 2016
Continuation PCTUS2014066829 · Nov 21, 2014
Provisional Application 61907808 · Nov 22, 2013
Related Publication 20210299404A1 · Sep 30, 2021
Cited By (3)
US 12,186,011 US 12,239,365 US 12,426,948